Trials / Recruiting
RecruitingNCT05040373
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
Patisiran-LNP Pregnancy Surveillance Program
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 10 (estimated)
- Sponsor
- Alnylam Pharmaceuticals · Industry
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.
Conditions
Timeline
- Start date
- 2020-08-01
- Primary completion
- 2030-10-12
- Completion
- 2030-10-12
- First posted
- 2021-09-10
- Last updated
- 2026-03-31
Locations
7 sites across 7 countries: United States, France, Germany, Italy, Netherlands, Portugal, Spain
Source: ClinicalTrials.gov record NCT05040373. Inclusion in this directory is not an endorsement.